Tokyo (JCN) Nov 14, 2005- Fuji Pharma has agreed with JCR Pharmaceuticals to terminate their joint development contract for JR-013, a drug candidate for treating renal anemia. Since November 2004, the two companies have collaborated in R&D for the candidate.
